Verve Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Collaborations revenue
Operating expenses:
Research and early development
General and administrative
Total operating expenses
Loss from operations
Other income:
Change in fair value of preferred stock tranche liability
Change in fair value of antidilution rights liability
Change in fair value of success payment liability
Interest and other income, net
Total other income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
Net loss per common share attributable to common stockholders, basic and diluted
Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted
Other comprehensive loss:
Unrealized gain (loss) on marketable securities
Comprehensive loss
Net loss per common share, basic
Net loss per common share, diluted
Weighted-average common shares used in net loss, basic
Weighted-average common shares used in net loss, diluted

Comments